Major Histocompatibility Complex-specific Recognition of Mls-1 Is Mediated by Multiple Elements of the T Cell Receptor

By David L. Woodland,*† Hedy P. Smith,* Sherri Surman,* Phuong Le,* Renren Wen,‡ and Marcia A. Blackman*‡

From the *Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105; and the †Department of Pathology, University of Tennessee, Memphis, Tennessee 38163

Summary

We have recently shown that recognition of the mouse mammary tumor virus 9-associated superantigen (vSAG-9) by murine Vβ17+ T cells is strongly influenced by the major histocompatibility complex (MHC) class II haplotype of the presenting cells, resulting in a form of MHC-restricted recognition. This finding was unexpected, because T cell recognition of another well-characterized retroviral superantigen, minor lymphocyte-stimulating antigen 1 (Mls-1), had been shown to be independent of the MHC haplotype of the presenting cell. To determine whether recognition of vSAG-9 and Mls-1 is fundamentally different, we undertook an extensive analysis of MHC haplotype influences on vSAG-9 and Mls-1 recognition by panels of T cell hybridomas. Our results show that, although most hybridomas recognized Mls-1 regardless of the MHC haplotype of the presenting cells, as previously described by others, some hybridomas exhibited unique patterns of MHC fine specificity. Thus, T cell recognition of vSAG-9 and Mls-1 is not fundamentally different, but the apparent differences can be explained in terms of frequency. The MHC fine specificity of individual Mls-1-reactive hybridomas was influenced by both Vβ and non-Vβ T cell receptor (TCR) elements. First, the influence of the Vβ element was apparent from the observation that Vβ8.2+ hybridomas were significantly more MHC specific in their recognition of Mls-1 than Vβ8.1 hybridomas. Second, a role for the TCR α chain was implicated from the distinct patterns of fine specificity of Mls-1 reactivity among a panel of transgenic hybridomas that expressed an identical B chain (Vβ8.1Dβ2Jβ2.3Cβ2). Sequence analysis revealed that junctional residues of the TCR α chain and/or Vα/Jα combinations influenced the MHC haplotype fine specificity for Mls-1. Third, Dβ/Jβ influences were implicated, in that the transgenic hybridomas expressed distinctive patterns of Mls-1 fine specificity not represented among Vβ8.1+ nontransgenic hybridomas. The findings that T cell recognition of endogenous superantigen is MHC specific, and that this specificity correlates with non-Vβ elements of the TCR, support the hypothesis that there is a direct interaction between the TCR and either polymorphic residues of the MHC class II molecule or haplotype-specific dominant peptides presented by class II.

Bacterial and retroviral superantigens are characterized by their ability to stimulate T cells based predominantly on the expression of specific TCR Vβ elements (1, 2), although non-Vβ elements of the receptor have recently been shown to have an influence on reactivity (3–6). MHC class II molecules are necessary for presentation of superantigens to T cells, but these responses are not classically MHC restricted, in that individual T cells are able to recognize a single superantigen presented in the context of multiple class II molecules. However, it has been shown that class II isotypes and alleles vary in their effectiveness as presenting molecules. For example, studies with murine clones and hybridomas specific for the mouse mammary tumor virus (Mtv)1-associated superantigen, Mls-1, have shown that I-E molecules tend to be stronger presenters than I-A molecules and that different MHC haplotypes can be ordered into a hierarchy where H-2k/H-2d are the strongest, and H-2d/H-2s are the weakest, presenters of Mls-1 (7–10). Based on these findings, it has been proposed that the class II molecule acts as a generic support for superantigen presentation at the cell surface and that the hierarchy of presentation reflects the relative binding affinity

1 Abbreviations used in this paper: Mtv, mouse mammary tumor virus; vSAG-9, Mtv-9-associated superantigen.
of individual superantigens to different MHC class II molecules (11, 12).

In contrast with this model, our recent studies with the Mtv-9-associated superantigen (vSAG-9) revealed that individual Vβ17+ T cell hybridomas were able to distinguish vSAG-9 presented by different MHC molecules, suggesting that under some circumstances, the class II molecule may play a more intimate role in the trimolecular interaction between superantigen, TCR, and MHC (13). The current studies were undertaken to determine why the recognition of vSAG-9 by T cell hybridomas should differ from the recognition of other retroviral superantigens, such as Mls-1. It is possible that this characteristic is unique to either the Vβ17 element of the TCR, or to the vSAG-9 moiety. Alternatively, individual Mls-1 reactive T cells may exhibit MHC haplotype specificity, but, because they are present at a lower frequency, have not been described. To distinguish these possibilities, we have analyzed panels of superantigen-reactive hybridomas for MHC haplotype specificity. We show here that the recognition of Mls-1 by some T cells is also critically dependent on the haplotype of the MHC molecule. In addition, we show that this fine specificity is controlled by non-Vβ elements of the TCR, thus implicating a direct interaction between the TCR and MHC during superantigen engagement, as we and others have previously suggested (13–18).

Materials and Methods

Mice. The generation and characterization of the TCR Vβ8.1 transgenic mice has been described elsewhere (19). For these studies we used a line of transgenic animals that had been repeatedly back-crossed with CBA/Ca (H-2k, Mls-1-) mice. All conventional mouse strains, BxH-7, SWR/J, C57BL/10J, B10.BR, CBA/J, CBA/Ca, C3H/HeJ, DBA/2, BALB/c, and D1.LtJ, were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained at the animal facility at St. Jude Children’s Research Hospital, under specific pathogen-free conditions.

Cell Lines. A20/2J (H-2d) and LBK (H-2d) are B cell lines that have been described elsewhere (20, 21). 1H10 and 3G9 are transfectants of A20/2J and LBK, respectively, that have been transfected with the Mtv-9 3’LTR and shown to express high levels of vSAG-9 (13, 22, 23). 2HCa-2 is a Vβ8.1/Vβ17+ hybridoma derived from BxH-7 and B10.BR mice. KE8 is a Vβ5+ hybridoma, which specifically recognizes Vβ5+ TCR (9). In this study we only analyzed hybridomas that: (a) were isolated from plates in which $<$25% of the wells were positive for hybridoma growth; (b) expressed high levels of the relevant Vβ and CD4 (determined by staining with GK1.5) (31); (c) secreted IL-2 in response to TCR ligation by immobilized anti-TCR antibodies; and (d) did not respond to superantigen-negative control cell lines or spleen cells (i.e., were not alloreactive). The two panels of Vβ5+ hybridomas derived from BxH-7 and B10.BR mice were an exception to this rule since only 10% of the Vβ5+ hybridomas stably expressed CD4, necessitating the analysis of CD4+ hybridomas. However, these hybridomas all expressed high levels of TCR and secreted IL-2 in response to immobilized MR9-4 (anti-Vβ5 mAb). All hybridomas were analyzed as soon as possible after fusion (within 3 wk) since their reactivity was strongest at this time, and were subsequently restested to confirm their patterns of fine specificity. The patterns of reactivity for each individual hybridoma were always consistent with the initial analysis, although the reactivities were sometimes weaker. Hybridomas were always tested against the entire panel of spleen cells (or transfectants) and controls within a single assay.

IL-2 Assays. 105 responding hybridomas were cultured either with 106 B cell transfectants (A20/2J, LBK, 1H10, 3G9), 106 LPS/IL-4-treated spleen cells (32, 33), or immobilized Vβ-specific antibodies in 250-μl cultures. After 24 h, supernatants were tested for IL-2 as previously described (32). 1 U of human IL-2 (R & D Systems, Minneapolis, MN) represents 160 U of IL-2 in our assay. Antibody inhibition studies were done in the standard stimulation assay except that purified antibodies (4 μg/ml) were added to the cultures.

cDNA Sequencing. PCR-amplified cytoplasmic RNA was sequenced as previously described (34). Briefly, cDNA was generated from RNA by reverse transcription and amplified by PCR using 5’ primers specific for the Va2 family and a 3’ Cα primer. This PCR product was then converted to ssDNA by unequal amplification in a second PCR using a 100:1 ratio of two internal nested primers and sequenced by the dideoxynucleotide termination method according to the sequencing protocol (U.S. Biochemical Corp., Cleveland, OH). All oligonucleotides used in this procedure have been previously described (6).

Results

MHC-specific Recognition of vSAG-9 by Vβ5+ and Vβ17+ T Cells. Previous studies had shown that individual Vβ7+ hybridomas were able to distinguish vSAG-9 moieties presented on different MHC molecules (13). To determine whether MHC specificity was a general property of T cells specific for vSAG-9, or unique to Vβ17+ T cells, we compared vSAG-9 reactivity of Vβ5+ hybridomas from BxH-7 (H-2d, Mtv-9-) mice and Vβ17+ hybridomas from SWR (H-2d, Mtv-9-) mice. 96 Vβ5+ and 90 Vβ17+/CD4+ hybridomas that secreted IL-2 in response to TCR ligation by the relevant Vβ antibodies were tested for their ability to specifically recognize vSAG-9 presented on either A20 (Aβ, Eβ) or LBK (Aβ, Eβ) cells transfected with the vSAG-9 gene (13, 22, 23). Expression of vSAG-9 on the transfectants was confirmed using a hybridoma, KE8, that recognizes vSAG-9 in the context of IL-2 for a further 2 d before fusion. The Vβ8.1+ and Vβ8.2+ hybridomas described in Fig. 2 arose in a single fusion of KJ16-stimulated T cells and were distinguished using the F23.2 antibody, which specifically recognizes Vβ8.2+ TCR (9). In this study we only analyzed hybridomas that: (a) were isolated from plates in which $<$25% of the wells were positive for hybridoma growth; (b) expressed high levels of the relevant Vβ and CD4 (determined by staining with GK1.5) (31); (c) secreted IL-2 in response to TCR ligation by immobilized anti-TCR antibodies; and (d) did not respond to superantigen-negative control cell lines or spleen cells (i.e., were not alloreactive). The two panels of Vβ5+ hybridomas derived from BxH-7 and B10.BR mice were an exception to this rule since only 10% of the Vβ5+ hybridomas stably expressed CD4, necessitating the analysis of CD4+ hybridomas. However, these hybridomas all expressed high levels of TCR and secreted IL-2 in response to immobilized MR9-4 (anti-Vβ5 mAb).
of both of these MHC haplotypes (13, and data not shown).
Analysis of the V85+ hybridomas revealed that only 40 of
96 (42%) responded to vSAG-9. Nonetheless, these hybridomas
were strongly dependent on the MHC haplotype of the presenting cell in their recognition of vSAG-9 (Fig. 1 A).
Whereas some hybridomas recognized vSAG-9 in the context of both H-2b and H-2d, others recognized vSAG-9 only in the context of one or the other of these haplotypes. These differences in fine specificity did not correlate with the expression of either Vβ5.1 or Vβ5.2 TCR elements (determined by MR9-4, anti-Vβ5.1/Vβ5.2 and MR9-8, anti-Vβ5.1 staining; data not shown) (26, 27). Thus, recognition of vSAG-9 by Vβ5+ T cells is highly dependent on the MHC haplotype of the presenting cell. The majority (71/90, 79%) of the Vβ17+/CD4+ hybridomas responded to vSAG-9, and many of these hybridomas recognized this superantigen in an MHC-specific manner, consistent with previous observations (Fig. 1 B).

Recognition of Mls-1 by Some T Cells Is MHC Specific. Most Vβ8.1+ and some Vβ8.2+ T cells have been shown to be Mls-1 reactive (9). To analyze the role of MHC molecules in this interaction, we generated a panel of Vβ8.1+ and Vβ8.2+ hybridomas from C57Bl/10 mice (H-2b, Mls-1+). Allogeneically, we characterized 17 Vβ8.1+/CD4+ and 31 Vβ8.2+/CD4+ hybridomas for their reactivity to the Mls-1 antigen presented on spleen cells expressing three different MHC haplotypes, H-2b, H-2d, and H-2k (CBA/J, DBA/2, D1.LP). Mls-1 expression on the spleen cells was confirmed with a well-characterized hybridoma, 2HCa-2, that is strongly reactive to Mls-1 presented in the context of all the MHC haplotypes tested (6). Mls-1 specificity among the hybridomas was confirmed using MHC-matched spleen cells that do not express Mls-1 (CBA/Ca, B10.D2, C3H, B10.BR, BALB/c, C57Bl/10). All 17 of the Vβ8.1+ hybridomas recognized the Mls-1 superantigen. A comparison of reactivity of individual hybridomas to Mls-1 presented by H-2b vs. H-2d (Fig. 2 A) and H-2b vs. H-2k (Fig. 2 B) revealed no evidence of MHC-specific recognition of Mls-1, contrasting strongly with the MHC-dependent reactivity of the Vβ17+ and Vβ8+ hybridomas to vSAG-9. In general, each hybridoma responded more strongly to Mls-1 presented by H-2b and H-2d than to Mls-1 presented by H-2k, consistent with the findings of others that there is a hierarchy of reactivity to Mls-1 presented by different MHC alleles and not by individual TCRs (7–10).

In contrast to the Vβ8.1+ hybridomas, Vβ8.2+ hybridomas varied greatly in their recognition of Mls-1 presented by different MHC class II alleles (Fig. 2, C and D). Although only 12 of the 31 Vβ8.2+ hybridomas (39%) were Mls-1 reactive, several (7/12) displayed considerable Mls-1 recognition of Vβ8.2+ hybridomas, which is not true for the other Vβ8.2+ hybridomas that were Mls-1 reactive (7/12) of these hybridomas recognized Mls-1 presented exclusively by either H-2b or H-2d. Relatively few
of Mls-1 presented by H-2a vs. H-2h (Fig. 3B). The distinctions in these phenotypes is clearest in a comparison of recognition by vBg.1 + hybridomas and was distributed into two major

patterns. All hybridomas were derived from Vβ8.1 transgenic mice in which the transgene has been repeatedly backcrossed onto CBA/CaJ (H-2k, Mls-1-). Altogether, 75 Vβ8.1+/CD4+ hybridomas (derived from a single fusion of KJ16-activated T cells) and 45 Vβ8.1+/Vα2+CD4+ hybridomas (derived from two separate fusions of B20.1-activated T cells) were identified that all secreted IL-2 in response to immobilized KJ16 (anti-Vβ8.1/Vβ8.2) antibody. For simplicity, only the 60 Vβ8.1+/CD4+ and 29 Vβ8.1+/Vα2+CD4+ transgenic hybridomas that responded specifically to Mls-1 presented in the context of H-2k, H-2d, or H-2b are shown. Each hybridoma was assayed two or three times to confirm the specificity pattern, and the results were always consistent with the initial analysis. The data presented are from the earliest assay of these hybridomas.

since H-2d is considered a strong presenter of Mls-1 to most Vβ8.1 T cells (9; see also Fig. 2, A and B). The finding that Vβ8.1 recognition of Mls-1 can also be strongly influenced by the MHC haplotype of the presenting cell indicates that there is no fundamental difference in recognition of Mls-1 by Vβ8.1+ and Vβ8.2+ T cells. In addition, the lack of MHC-specific recognition among nontransgenic Vβ8.1+ hybridomas suggests that these cells are represented at only a low frequency in normal mice but are amplified in the Vβ8.1 transgenic animals due to a skewing of the TCR repertoire.

Contribution of the TCR α Chain to MHC-specific Patterns of Mls-1 Recognition. Because all of the hybridomas generated from the transgenic mouse express an identical β chain, any contribution of the TCR to specificity is controlled by the α chain. This is consistent with our findings (6) and others' (4, 5) that the TCR α chain plays a role in superantigen recognition. To further investigate the role of the α chain in generating the two dominant specificity phenotypes among the transgenic hybridomas, we took advantage of a Vα2-
specific antibody. Hybridomas that expressed V\(\alpha\)2* TCR are identified by open symbols in Fig. 3, A and B. The V\(\alpha\)2* hybridomas were very unequally distributed between the two phenotypes, in that the majority (7/8) did not recognize Mls-1 in the context of H-2\(^d\). The V\(\alpha\) element of the TCR influences the MHC fine specificity of Mls-1 recognition.

To extend the correlation between fine specificity for Mls-1 and \(\alpha\) chain usage among the V\(\alpha\)2* hybridomas, a larger panel of hybridomas was generated from transgenic T cells that had been activated with immobilized V\(\alpha\)2-specific mAb. Analysis of 29 V\(\alpha\)2*/CD4* hybridomas for their recognition of Mls-1 presented on different MHC haplotypes (Fig. 3, C and D) confirmed the finding that V\(\alpha\)2+ transgenic hybridomas had a distinct pattern of Mls-1 specificity. Again, the V\(\alpha\)2* hybridomas were not equally distributed among the two phenotypes described for the unselected transgenic hybridomas, in that most of the hybridomas did not recognize Mls-1 presented in the context of H-2\(^d\) (Fig. 3 D). Also, the V\(\alpha\)2* hybridomas appeared to be more discriminatory in their recognition of Mls-1 presented by either b or k (Fig. 3 C). Inhibition studies with MHC class II-specific antibodies revealed that the two patterns of fine specificity did not correlate with the recognition of I-A vs. I-E, although interestingly, none of the hybridomas recognized Mls-1 exclusively in the context of I-A\(^k\) (data not shown).

The Mls-1-reactive V\(\alpha\)2+ transgenic hybridomas could be classified into three distinct groups based on their specificity for Mls-1. Groups 1 and 2 were characterized by their preferential recognition of Mls-1 on either H-2\(^k\) or H-2\(^d\), but lack of response to Mls-1 presented by H-2\(^d\). The third group was distinguished by the (nonexclusive) recognition of Mls-1 presented by H-2\(^d\). To determine what component of the TCR \(\alpha\) chain controlled the three patterns of MHC specificity among the V\(\alpha\)2 hybridomas, we identified the \(\alpha\) family member, junctional, and J\(\alpha\) sequences in each hybridoma. As shown in Table 1, usage of particular V\(\alpha\)2 family members did not correlate directly with fine specificity for Mls-1. For example, the V\(\alpha\)2.3 and V\(\alpha\)2.HC\(a\)8 elements were expressed frequently among hybridomas with distinctive patterns of Mls-1 recognition. Similarly, in general, there was no direct correlation between Mls-1 reactivity and J\(\alpha\) usage. However, there was a restricted use of J\(\alpha\) elements in group 1 hybridomas (k>b) in that 8 of 17 of the hybridomas used J\(\alpha\)17, J\(\alpha\)24, and J\(\alpha\)28 elements. These J\(\alpha\) elements were absent in Mls-1-reactive hybridomas with other patterns of fine specificity (groups 2 and 3). Interestingly, two hybridomas (4-77 and 4-59) that differed only in junctional residues expressed distinctive patterns of fine specificity for Mls-1. This is consistent with previous studies that have implicated \(\alpha\) chain junctional sequences in Mls-1 reactivity of transgenic hybridomas (6). Taken together, these data demonstrate that different elements of the \(\alpha\) chain contribute to the MHC fine specificity of Mls-1 recognition, although we have not identified a simple correlation between MHC specificity and usage of particular \(\alpha\) chain elements. These observations are consistent with the hypothesis that there is a direct interaction between the MHC molecule and TCR during superantigen engagement (11, 13–18).

**Discussion**

Our previous studies had shown that recognition of the Mtv-9-associated superantigen, vSAG-9, by V\(\beta\)5* T cells was strongly influenced by the MHC haplotype of the presenting cell (13). However, this finding contrasted with the large body of work regarding T cell recognition of another retroviral superantigen, Mls-1. Although different MHC molecules clearly varied in their capacity to present Mls-1, individual hybridomas or clones were not reported to distinguish between Mls-1 moieties presented on different MHC molecules (7–10). To better understand the differences between T cell recognition of vSAG-9 and Mls-1, we have analyzed the specificities of several panels of hybridomas and shown that the Mls-1 superantigen can also be recognized in an MHC-specific fashion by some T cells. Thus, these studies demonstrate that there is no fundamental difference in the
Table 1. **Sequence Analysis of Mls-1-reactive, Vα2+ Hybridomas Derived from a Vβ8.1 Transgenic Mouse**

IL-2 secreted in response to:

| Hybridoma* | CBA/J (H-2<sup>k</sup>) | DBA/2 (H-2<sup>b</sup>) | D1.LP (H-2<sup>a</sup>) | KJ16 | Sequence |
|------------|--------------------------|--------------------------|--------------------------|------|----------|
|            | U/ml                     |                          |                          |      | Vα<sup>†</sup> | N<sup>§</sup> | Jα |
| k>b        |                          |                          |                          |      |           |           |    |
| 6-7        | 20                       | -                        | -                        | 1,280| HCa8     | E          | 34 |
| 6-63       | 20                       | -                        | -                        | 2,560|           | 2.5        | 17 |
| 6-132      | 20                       | -                        | -                        | 640  |           | 2.3        | 20 |
| 4-77       | 20                       | -                        | -                        | 2,560|           | 2.3        | GD |
| 4-32       | 40                       | -                        | -                        | 2,560|           | 2.3        | 24 |
| 4-19       | 40                       | -                        | -                        | 2,560|           | 2.3        | 16 |
| 6-2        | 40                       | -                        | -                        | 80   |           | 2.3        | N  |
| 6-66       | 40                       | -                        | -                        | 320  |           | 2.3        | 24 |
| 4-57       | 40                       | -                        | -                        | 10,240|         | 2.3        | E  |
| 6-186      | 160                      | -                        | -                        | 2,560|           | 2.3        | EG |
| 4-103      | 320                      | -                        | -                        | 640  | HCa8     | (A)        | 17 |
| 6-1        | 320                      | -                        | 160                      | 1,280|           | 2.3        | Y  |
| 4-34       | 320                      | -                        | 40                       | 2,560| HCa8     | G          | 41 |
| 4-10       | 320                      | -                        | 80                       | 5,120| HCa8     | –          | 28 |
| 6-178      | 640                      | -                        | 80                       | 2,560|           | 2.3        | –  |
| 4-104      | 640                      | -                        | 160                      | 2,560|           | 2.3        | E  |
| 4-4        | 1,280                    | -                        | 160                      | 2,560|           | 2.3        | [NI]   |
| b>k        |                          |                          |                          |      |           |           |    |
| 6-122      | –                        | –                        | 20                       | 640  |           | 2.3        | V  |
| 4-101      | –                        | –                        | 40                       | 1,280| 4HCa-101  | SG         | 34 |
| 4-46       | –                        | –                        | 40                       | 640  | HCa8     | R          | 37 |
| 4-75       | 20                       | –                        | 40                       | 2,560| 4HCa-75   | D          | 32 |
| 4-59       | –                        | –                        | 160                      | 2,560|           | 2.3        | F  |
| 4-24       | 20                       | –                        | 160                      | 2,560| HCa8     | ER         | 49 |
| 6-189      | 40                       | –                        | 160                      | 2,560| HCa8     | KG         | 40 |
| 4-106      | 20                       | –                        | 640                      | 2,560| HCa8     | [NI]       | 25 |
| d-reactive |                          |                          |                          |      |           |           |    |
| 5-52       | >1,280                   | >1,280                   | >1,280                   | 1,280| HCa8     | [NI]       | 15 |
| 6-35       | 640                      | 640                      | 320                      | 5,120| 4HCa-19   | (R)TL      | 32 |
| 6-68       | 320                      | 40                       | –                        | 1,280| HCa8     | [NI]       | 30 |
| 6-124      | –                        | 80                       | –                        | 320  | HCa8     | A          | 15 |

* The Vα2+ hybridomas presented here are derived from three separate fusions, designated by the prefixes 4, 5, and 6 in the hybridoma name. All hybridomas were generated from Vβ8.1 transgenic CD4+ cells that were activated with either B20.1 (anti-Vα2, fusions 4 and 6; shown in Fig. 3, C and D) or KJ16 (anti-Vβ8.1/Vβ8.2, fusion 5; shown in Fig. 3, A and B). Hybridoma reactivity is presented as IL-2 secretion in response to Mls-1+ spleen cells of the indicated MHC haplotypes or immobilized KJ16 antibody. IL-2 assays and TCR α chain sequencing was performed as described in Materials and Methods. The groupings k>b, b>k, and d-reactive indicate the relative MHC specificity of the hybridomas for Mls-1.

† The sequences of Vα2.HCa8, Vα2.3, and Vα2.5 have been previously published (6, 36, 37). The sequences of 4HCa-19, 4HCa-75, and 4HCa-101 Vα2 elements will be published separately.

§ Amino acid residues in parentheses were encoded by the Vα gene. [NI], not identified.
Figure 4. IL-2 secretion by VB5+ hybridomas derived from (A) B10.BR (H-2k, Mtv-9+) and (B) BxH-7 (H-2k, Mtv-9-) mice in response to Mtv-9-associated superantigen, vSAG-9, presented by either (H-2k, Mtv-9+) and (BxH-7 (H-2k, Mtv-9-) mice in response to immobilized MR.9-4 (anti-V35) antibody even though many of them did not specifically respond to vSAG-9 presented on the transfectants. Each hybridoma was assayed two or three times to confirm the specificity pattern, and the results were always consistent with the initial analysis. The data presented are from the earliest of these hybridomas.

We and others have previously shown influences of non-Vβ elements of the TCR on endogenous superantigen recognition (3–6). The data presented here extend these studies to show that these non-Vβ influences correlate with the MHC fine specificity of individual hybridomas. First, a direct role for the TCR α chain was apparent from the distinct patterns of Mls-1 fine specificity among VB8.1+ transgenic hybridomas, which all expressed an identical β chain. Sequence analysis of some of these hybridomas did not reveal a direct correlation between specificity and Vα family member usage or Jα usage, suggesting that functional residues or combinations of these elements control this reactivity. Second, a role for non-Vβ elements of the β chain in Mls-1 fine specificity was apparent from the observation that the VB8.1+ transgenic hybridomas expressed distinct patterns of MHC specificity that were not found among nontransgenic VB8.1+ hybridomas. It is likely that restriction of the repertoire to a single transgenic β chain has amplified a minor population of T cells with distinctive specificities in the transgenic animals.

Although the molecular mechanism underlying MHC-specific recognition of retroviral superantigens remains to be determined, the involvement of non-Vβ elements suggests two possibilities. One possibility is that non-Vβ elements affect the binding of superantigen to the TCR, either directly by contacting superantigen or indirectly by inducing a conformational change in the superantigen binding site on Vβ. However, this mechanism is unlikely to explain differences in MHC specificity as reported here. An alternative possibility, and one that we and others have proposed previously, is that MHC-specific recognition of superantigen is mediated by a direct interaction between the TCR and the MHC class II molecules during the formation of a superantigen/TCR/MHC complex (11, 13–18). For example, interactions between polymorphic residues of the MHC molecule (and/or bound peptide) and the α chain of the TCR might act to either stabilize or disrupt formation of a superantigen/TCR/MHC complex. In the case of the β chain, non-Vβ components could affect fine specificity either by selecting a repertoire of α chains that confer distinctive Mls-1 specificities on the T cell, or by directly contacting the MHC molecule itself. We are further investigating these proposed interactions by mutagenesis experiments in which mutations in the TCR, MHC class II molecules, and Mls-1 will be analyzed for their influence on MHC-restricted recognition.

In the absence of structural information, it is difficult to predict how non-Vβ elements might interact with the MHC during superantigen recognition (39, 40). One possibility is that the interaction is the same as during recognition of conventional antigen/MHC. Alternatively, it is possible that MHC/TCR contact points involved in recognition of superantigen vs. conventional Ag/MHC might be significantly different. For example, the superantigen might rotate the TCR out of its normal docking orientation, or might induce significant conformational changes in the TCR or MHC structure. Indirect support for the idea that the TCR/MHC interaction is unconventional comes from our study of Mls-1-reactive, VB8.2+ hybridomas. Since these hybridomas were derived from a C57Bl/10 mouse, the parental T cells should have been positively selected by, and presumably have a weak affinity for, H-2b molecules. If favorable TCR/MHC interactions are required for the recognition of Mls-1 by VB8.2+ T cells, then one might have expected to see significant numbers of hybridomas that preferentially recognized Mls-1 in the context of H-2b. However, this was not the case, suggesting that positive selection in the thymus had not directly influenced the fine specificity of the T cells to Mls-1, and supporting the idea that TCR/MHC interactions differ between superantigen and classical peptide recognition. An unconventional TCR/MHC interaction during superantigen engagement might explain reports suggesting that signaling events associated with TCR recognition of superantigen are different from those induced by recognition of conventional antigen/MHC (41–43).

An important question raised by these studies is why superantigen recognition of only some T cell hybridomas is MHC specific. We have previously proposed that this reflects differences in affinity between the superantigen and TCR (13). Thus, if the affinity between the TCR and the superantigen is weak, the stability of the MHC/TCR/superantigen complex is likely to be strongly influenced by stabilizing or disruptive interactions between the TCR and polymorphic residues of MHC (and/or bound peptide), resulting in a high frequency of MHC specificity. In contrast, if the TCR/superantigen interaction is strong, direct TCR/MHC interactions are likely to have less influence on the stability of the trimolecular complex, thus resulting in a lower frequency of MHC specificity. In this case, recognition of superantigen would reflect the hierarchy that is thought to be controlled by variation in the affinity of the superantigen for different MHC class II molecules (12). The finding that MHC-specific
recognition of Mls-1 was frequent among Vβ8.2⁺ and infrequent among Vβ8.1⁺ hybridomas is consistent with this hypothesis. Although it is not yet possible to directly measure the affinities of individual TCRs for Mls-1, several observations indirectly suggest that Vβ8.1⁺ T cells are generally of higher affinity than Vβ8.2⁺ T cells. First, a much higher frequency of Vβ8.1⁺ hybridomas respond to Mls-1 in these experiments, 100% of Vβ8.1 hybridomas, compared with 39% of Vβ8.2⁺ hybridomas, recognized Mls-1 on the MHC haplotypes tested. Second, Vβ8.1⁺ T cells are effectively clonally eliminated from the periphery of Mls-1-expressing mice, whereas Vβ8.2⁺ T cells are relatively unaffected (9). Third, mutational analysis has suggested that glycosylation sites on the Vβ8.2 element partially obscure the Mls-1 binding site. Removal of these sites by mutation restores Mls-1 recognition in some, but not all, Vβ8.2⁺ TCRs (35, 44). Additional support for the hypothesis comes from the unexpected high frequency of MHC specificity of the Vβ8.1 transgenic hybridomas. For reasons that are as yet unclear, this particular β chain appears to have a relatively low affinity for Mls-1. For example, Mls-1 mediates only poor clonal deletion of transgenic T cells in these animals (6, 19) and in the studies presented here, only 80% of transgenic T cells were Mls-1 reactive. Thus, apparent differences in affinity of Vβ8.1, Vβ8.2, and transgenic Vβ8.1 hybridomas for Mls-1 correlate with the different degrees of MHC specificity in their Mls-1 recognition.

The finding that individual T cells have different fine specificities for retroviral superantigens has significance for repertoire selection in vivo. We speculated that some T cells predicted to be superantigen reactive on the basis of their Vβ usage would fail to be clonally eliminated during ontogeny because they were unable to recognize the superantigen presented in the context of self-MHC. Analysis of vSAG-9 reactivity among Vβ5⁺ hybridomas from B10.BR (Mtv-9⁺, H-2k) mice revealed that while vSAG-9/H-2k reactivity had been purged (either by deletion or anergy), it was still possible to detect vSAG-9/H-2k reactivity. These data suggest that clonal deletion is incomplete, at least in part, because some T cells do not recognize the superantigen presented in the context of self-MHC molecules. This hypothesis is difficult to test directly due to the interference of strong alloreactive responses and the possibility that the activation of T cells by Mls-1 on syngeneic and allogeneic MHC may induce alternative activation pathways. For example, it has been reported that neonatal induction of tolerance to Mls-1 with allogeneic spleen cells does not result in the peripheral deletion of Mls-1-reactive T cells, contrasting with the strong clonal deletion of Mls-1-reactive T cells induced by syngeneic spleen cells (45, 46).

Taken together, the data presented in this paper show that T cell recognition of retroviral superantigens, such as vSAG-9 and Mls-1, can be strongly influenced by the MHC molecule, resulting in distinct patterns of fine specificity. Moreover, the clear involvement of both α and β chain elements of the TCR suggests that there is a direct interaction between the TCR and MHC molecule during superantigen engagement. These findings have great significance for our understanding of T cell reactivity and tolerance to retroviral superantigens.

We thank Twala Hogg, Betsy Sidel, and Jim Houston for excellent technical assistance; Dr. John Freed for generously providing purified reagents for the antibody inhibition studies; Dr. Bernard Malissen for providing the Vα2-specific antibody; and Drs. Ron Corley, Geoffrey Cole, Alison Deckhut, and Mary Pat Happ for critically reviewing the manuscript.

This work was supported by Cancer Center Support Grant CA-21765 (D. L. Woodland); National Institutes of Health grant AI-31489 and Bristol-Myers Cancer Grant Award (both to M. A. Blackman); and the American Lebanese Syrian Associated Charities (ALSAC).

Address correspondence to David L. Woodland, Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN 38105.

Received for publication 8 October 1992.

References
1. Janeway, C. A. 1991. Selective elements for the Vβ region of the T cell receptor: Mls and the bacterial toxic mitogens. Adv. Immunol. 50:1.
2. Woodland, D.L., and M.A. Blackman. 1992. Retroviral superantigens and T cells. Int. Rev Immunol. 8:311.
3. Candeias, S., C. Waltzinger, C. Benoist, and D. Mathis. 1991. The Vβ17⁺ T cell repertoire: skewed Jβ usage after thymic selection; dissimilar CDR3s in CD4⁺ versus CD8⁺ cells. J. Exp. Med. 174:989.
4. Kanagawa, O., B.A. Nussrallah, M.E. Wiebenga, K.M. Murphy, H.C. Morse III, and F.R. Carbone. 1992. Murine AIDS superantigen reactivity of the T cells bearing Vβ5 T cell antigen receptor. J. Immunol. 149:9.
5. Vaccio, M.S., O. Kanagawa, K. Tomonari, and R.J. Hodes. 1992. Influence of T cell receptor Vα expression on Mls1 superantigen-specific T cell responses. J. Exp. Med. 175:1405.
6. Smith, H., P. Le, D.L. Woodland, and M.A. Blackman. 1992. T cell receptor α-chain influences reactivity to Mls-1 in Vδ8.1.
transgenic mice. J. Immunol. 149:887.
7. Peck, A.B., C.A. Janeway, Jr., and H. Wiggell. 1977. T lymphocyte responses to Mls locus antigens involve recognition of I region gene products. Nature (Lond.). 266:840.
8. DeKruyff, R., S. Ju, J. Laning, H. Cantor, and M. Dorf. 1986. Activation requirements of cloned inducer T cells. III. Need for two stimulator cells in the response of a cloned line to Mls determinants. J. Immunol. 137:1109.
9. Kappler, J.W., U. Staerz, J. White, and P. Marrack. 1988. Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex. Nature (Lond.). 332:35.
10. Pullen, A.M., P. Marrack, and J.W. Kappler. 1988. The T cell repertoire is heavily influenced by tolerance to polymorphic self-antigens. Nature (Lond.). 335:801.
11. Janeway, Jr., C.A., J. Yagi, P.J. Conrad, M.E. Katz, B. Jones, S. Vroegop, and S. Buxser. 1989. T-cell responses to Mls and to bacterial proteins that mimic its behavior. Immunol. Rev. 107:61.
12. Herman, A., J.W. Kappler, P. Marrack, and A.M. Pullen. 1991. Superantigens: Mechanism of T-cell stimulation and role in immune responses. Annu. Rev. Immunol. 9:745.
13. Blackman, M.A., F.E. Lund, S. Surman, R.B. Corley, and D.L. Woodland. 1992. Major histocompatibility-restricted recognition of retroviral superantigens by Vβ17+ T cells. J. Exp. Med. 167:275.
14. Fleischer, B., and H.-W. Mittrucker. 1991. Evidence for T cell receptor-HLA class II molecule interaction in the response to superantigenic bacterial toxins. Eur. J. Immunol. 21:1331.
15. Herman, A., G. Croteau, R.-P. Sekaly, J. Kappler, and P. Marrack. 1990. HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells. J. Exp. Med. 172:709.
16. Yagi, J., S. Rath, and C.A. Janeway, Jr. 1991. Control of T cell responses to staphylococcal enterotoxins by stimulator cell MHC class II polymorphism. J. Immunol. 147:1398.
17. Mollick, J.A., M. Chintagumpala, R.G. Cook, and R.P. Rich. 1991. Staphylococcal exotoxin activation of T cells. Role of exotoxin-MHC class II binding affinity and class II isotype. J. Immunol. 146:463.
18. Kappler, J.W., A. Herman, J. Clements, and P. Marrack. 1992. Mutations defining functional regions of the superantigen staphylococcal enterotoxin B. J. Exp. Med. 175:387.
19. Blackman, M.A., H.-G. Burgert, D.L. Woodland, E. Palmer, J.W. Kappler, and P. Marrack. 1990. A role for clonal inactivation in T cell tolerance to Mls-1. Nature (Lond.). 345:540.
20. Kim, K.J., C. Kanellopoulos-Langevin, R.M. Merwin, D.H. Sachs, and R. Asofsky. 1979. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122:549.
21. King, L.B., and R.B. Corley. 1989. Characterization of a presecretory phase in B cell differentiation. Proc. Natl. Acad. Sci. USA. 86:2814.
22. Woodland, D.L., F.E. Lund, M.P. Happ, M.A. Blackman, E. Palmer, and R.B. Corley. 1991. Endogenous superantigen expression is controlled by mouse mammary tumor proviral loci. J. Exp. Med. 174:1255.
23. Lund, F.E., T.D. Randall, D.L. Woodland, and R.B. Corley. 1992. MHC class II limits the functional expression of endogenous superantigens in B cells. J. Immunol. In press.
24. White, J., M. Blackman, J. Bill, J. Kappler, P. Marrack, D.P. Gold, and W. Born. 1989. Two better cell lines for making hybridomas expressing specific T cell receptors. J. Immunol. 143:1822.
25. Ledbetter, J.A., and L.A. Herzenberg. 1979. Xenogeneic mono-clonal antibodies to mouse differentiation antigens. Immunol. Rev. 47:63.
26. Bill, J., O. Kanagawa, J. Linten, Y. Utsunomiya, and E. Palmer. 1990. Class I and Class II MHC gene products differentially affect the fate of Vβ5 bearing thymocytes. J. Mol. Cell. Immunol. 4:269.
27. Kanagawa, O., Y. Utsunomiya, J. Bill, E. Palmer, M.W. Moore, and F.R. Carbone. 1991. Conformational difference of T cell antigen receptors revealed by monoclonal antibodies to mouse Vβ5 T cell receptor for antigen determinants. J. Immunol. 147:1307.
28. Kappler, J.W., T. Wade, J. White, E. Kushnir, M. Blackman, J. Bill, N. Roehm, and P. Marrack. 1987. A T cell receptor Vβ segment that imparts reactivity to a class II major histocompatibility complex product. Cell. 49:263.
29. Haskins, K., C. Hannum, J. White, N. Roehm, R. Kubo, J. Kappler, and P. Marrack. 1983. The major histocompatibility complex-restricted antigen receptor on T cells. VI. An antibody to a receptor allotype. J. Exp. Med. 160:452.
30. Pircher, H., N. Rebai, M. Greetrup, C. Grejour, D.E. Speiser, M.P. Happ, E. Palmer, R. Zinkernagel, H. Hengartner, and B. Malissen. 1992. Preferential positive selection of Vα2*CD8* T cells in mouse strains expressing both H-2K and T cell receptor Vα haplotypes: determination with a Vα2-specific monoclonal antibody. Eur. J. Immunol. 22:399.
31. Dialynas, D., D. Wilde, P. Marrack, A. Pierres, K. Wall, W. Havran, G. Otten, M. Loken, M. Pierres, J. Kappler, and F. Fisch. 1983. Characterization of the murine antigenic determinant designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen reactivity. Immunol. Rev. 74:29.
32. Woodland, D.L., M.P. Happ, J. Bill, and E. Palmer. 1990. Requirement for cotolerogenic gene products in the clonal deletion of I-E reactive T cells. Science (Wash. DC). 247:946.
33. Gollob, K.J., and E. Palmer. 1991. The physiological expression of two superantigens in the BDF1 mouse. J. Immunol. 147:2447.
34. Bill, J., J. Yague, V.B. Appel, J. White, G. Horn, H.A. Erlich, and E. Palmer. 1989. Molecular genetic analysis of 178 I-Aαβ-reactive T cells. J. Exp. Med. 169:115.
35. Pullen, A.M., T. Wade, P. Marrack, and J.W. Kappler. 1990. Identification of the region of the T cell receptor β chain that interacts with the self superantigen Mls-1. Cell. 61:1365.
36. Urban, J.L., V. Kumar, D.H. Kono, C. Gomez, S.J. Horvath, J. Clayton, D.G. Ando, E.E. Sercarz, and L. Hood. 1988. Restricted use of T cell receptor V β genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell. 54:577.
37. Thompson, S.D., M. Larche, A.R. Manzo, and J.L. Hurwitz. 1992. Diversity of T cell receptor alpha gene transcripts in the newborn and adult periphery. Immunogenetics. 36:95.
38. Blackman, M., J. Kappler, and P. Marrack. 1990. The role of the T cell receptor in positive and negative selection of developing T cells. Science (Wash. DC). 248:1335.
39. Davis, M.M., and P.J. Bjorkman. 1988. T-cell antigen receptor genes and T cell recognition. Nature (Lond.). 334:395.
40. Jorgensen, J.L., P.A. Bjorkman. 1988. T-cell antigen receptor genes and T cell recognition. Nature (Lond.). 334:395.
41. O'Rourke, A.M., M.F. Mescher, and S.R. Webb. 1990. Activation of polyphosphinositide hydrolysis in T cells by H-2 alloantigens but not Mls determinants. Science (Wash. DC).
42. Liu, H., M.A. Lampe, M.V. Iregui, and H. Cantor. 1991. Conventional antigen and superantigen may be coupled to distinct and cooperative T-cell activation pathways. *Proc. Natl. Acad. Sci. USA.* 88:8705.

43. Payne, J., and B.T. Huber. 1992. Minor lymphocyte stimulatory antigen-bearing stimulator cells require lipopolysaccharide activation to induce programmed cell death in T cell hybridomas. *J. Immunol.* 149:1571.

44. Pullen, A.M., J. Bill, R.T. Kubo, P. Marrack, and J.W. Kappler. 1991. Analysis of the interaction site for the self superantigen Mls-1* on T cell receptor Vβ. *J. Exp. Med.* 173:1183.

45. Speiser, D.E., R. Brandle, R.K. Lees, R. Schneider, R.M. Zinkernagel, and H.R. MacDonald. 1991. Neonatal tolerance to Mls-1* determinants: deletion or anergy of Vβ6* T lymphocytes depending upon MHC compatibility of neonatally injected cells. *Int. Immunol.* 3:127.

46. Dannecker, G., S. Mecheri, and M.K. Hoffmann. 1991. Induction of neonatal tolerance to the Mls-1* self-antigen. Time kinetics and MHC restriction. *J. Immunol.* 147:2833.